Piper Sandler Maintains Overweight on Nektar Therapeutics, Raises Price Target to $192

Benzinga Newsdesk www.benzinga.com Positive 88.0%

Neg 0% Neu 0% Pos 88%

Piper Sandler analyst Yasmeen Rahimi maintains Nektar Therapeutics (NASDAQ:NKTR) with a Overweight and raises the price target from $105 to $192.